TABLE 1.
Baseline characteristics of the study
|
Characteristic
|
Monotherapy, n (%) | Dual Therapy, n (%) |
P
Value |
|
n = 73
|
n = 35
|
||
| Mean age, y (95% CI) | 43.8 (39.8, 47.4) | 46.1 (41.3, 50.9) | .296 |
| Female at birth | 36 (49.3) | 19 (54.3) | .629 |
| White | 36 (49.3) | 23 (65.7) | .109 |
| African American | 29 (39.7) | 11 (31.4) | .403 |
| Mean weight, kg (95% CI) | 90.85 (83.37, 98.33) | 86.51 (78.71, 94.32) | .474 |
| Concurrent scheduled antipsychotic for switching to clozapine | 37 (50.7) | 19 (54.3) | .726 |
| Concurrent scheduled antipsychotic for multiple antipsychotic regimen | 15 (20.5) | 6 (17.1) | .676 |
| Concurrent antidepressant | 27 (37.0) | 12 (34.3) | .784 |
| Concurrent CYP1A2/3A4 inhibitora | 5 (6.8) | 1 (2.9) | .397 |
| Ciprofloxacin | 2 (2.7) | 0 (0) | .323 |
| Fluconazole | 1 (1.4) | 0 (0) | .826 |
| Fluvoxamine | 2 (2.7) | 1 (2.9) | .954 |
| Concurrent CYP1A2/3A4 inducera | 15 (20.5) | 12 (34.3) | .240 |
| Carbamazepine | 2 (2.7) | 1 (2.9) | .972 |
| Oxcarbazepine | 1 (1.4) | 1 (2.9) | .592 |
| Armodafinil | 1 (1.4) | 0 (0) | .826 |
| Phenytoin | 1 (1.4) | 0 (0) | .826 |
| Smoking >10 cigarettes/d | 10 (13.7) | 10 (28.6) | .063 |
a
Concurrent CYP1A2 and CYP3A4 inhibitors and inducers were screened based off FDA classification.10